- Published
- 06 August 2021
- Journal article
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
- Authors
-
- Source
- The Lancet
Abstract
Background
Methods
Findings
Interpretation
Rights
Crown Copyright © 2021 Published by Elsevier Ltd.
Cite as
Liu, X., Shaw, R., Stuart, A., Greenland, M., Aley, P., Andrews, N., Cameron, C., Charlton, S., Clutterbuck, E., Collins, A., Dinesh, T., England, A., Faust, S., Ferreira, D., Finn, A., Green, C., Hallis, B., Heath, P., Hill, H., Lambe, T., Lazarus, R., Libri, V., Long, F., Mujadidi, Y., Plested, E., Provstgaard-Morys, S., Ramasamy, M., Ramsay, M., Read, R., Robinson, H., Singh, N., Turner, D., Turner, P., Walker, L., White, R., Nguyen-Van-Tam, J., Snape, M. & Com-COV Study Group 2021, 'Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial', The Lancet, 398(10303), pp. 856-869. https://doi.org/10.1016/S0140-6736(21)01694-9